Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

GlycoEra

Request full access

GlycoEra’s innovative CustomGlycan platform unlocks the power of glycan-mediated biology to develop a pipeline of novel biologics for a broad range of indications

Schlieren, SwitzerlandFounded 2020Biotech & Life Sciences

About GlycoEra

GlycoEra is a pioneering biotechnology startup that specializes in the degradation of extracellular proteins. The company operates in the pharmaceutical industry, specifically in the development of transformative medicines. Their unique approach involves the precise degradation of circulating and membrane proteins, which has shown promising results in animal models.

GlycoEra's business model revolves around the development and commercialization of their proprietary technology. This technology allows for the modulation of the speed and depth of target protein degradation, which in turn influences the durability of the response. This means that they can control how quickly and how much of a specific protein is degraded, which can be crucial in the treatment of various diseases.

The company's primary clients are likely to be in the healthcare sector, including hospitals, clinics, and other healthcare providers. They may also be involved in partnerships with other pharmaceutical or biotech companies for the development and distribution of their products.

GlycoEra's revenue generation strategy is likely to be based on the sales of their developed drugs and licensing their technology to other companies. As a biotech startup, they may also rely on funding from investors who see potential in their innovative approach to medicine.

In summary, GlycoEra is a biotech startup that uses a unique approach to degrade extracellular proteins for the development of transformative medicines. They operate in the pharmaceutical industry, serving healthcare providers and potentially partnering with other companies in the sector. Their revenue is likely generated from the sales of their products and licensing their technology.

Source: Dealroom company data

At a glance

Status
Operational
Employees
30
Open positions
6
Dealroom signal
65.9/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Antibodies, Autoimmune, Immune System, Synthetic Biology, Biotech and Pharma, Woman Founder, proteomics, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing May 2025 $130M $520M Sofinnova Partners · 5AM Ventures · Qatar Investment Authority · MP Healthcare Venture Management ↗
SERIES AOther financing Jan 2024 — — 5AM Ventures · Roche Venture Fund · Sofinnova Partners · Bristol-Myers Squibb ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

GlycoEra website traffic

Latest recorded traffic for GlycoEra is 2.5K monthly website visits, up 47.1% over the last three months. GlycoEra's team declined 11.8% over the past year.

Latest monthly visits2.5K 3-month web change+47.1% 1-year team growth-11.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

GlycoEra in the Schlieren ecosystem

Live from Dealroom

The GlycoEra office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A12 investors entered at this stage

  • Sofinnova Partners
  • 5AM Ventures
  • LimmaTech Biologics
  • Roche Venture Fund
  • Bristol-Myers Squibb
  • Novo Holdings
  • Qatar Investment Authority
  • MP Healthcare Venture Management
  • Sixty Degree Capital
  • LifeArc Ventures
  • Agent Capital
  • Catalio Capital Management

Other known investors1 additional known investor

  • Grow Cluster Wädenswil
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See GlycoEra’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.